The price of DTC TV ad reviews
Executive Summary
FDA is charging pharmaceutical companies $41,390 to review a direct-to-consumer television ad during fiscal year 2008. The fees are based on company commitments to submit 151 ads for review and the need to generate $6.25 million to pay for FDA review activities and set up an operating reserve fund. The FDA Amendments Act, which establishes the voluntary DTC user fee program, requires collection of the fees within 120 days of the law's Sept. 27 enactment (1"The Pink Sheet" Nov. 26, 2007, p. 5). FDA is writing guidance on submission contents, format and procedures, but has given no date for its release...
You may also be interested in...
FDA Begins Reviewing DTC Ads As User Fee Program Faces Pay Or Die Deadline
Industry already has submitted 12 direct-to-consumer television ads to FDA for pre-review through the new DTC user fee program
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.